Literature DB >> 95419

Late complications of retrolental fibroplasia.

W Tasman.   

Abstract

A modified classification of cicatricial RLF has been presented. Particular emphasis is placed on myopia, one of the hallmarks of grade i cicatricial RLF. Whether or not this is axial myopia is still open to question, but since the more myopic eye was usually longer by ultrasonic measurement than the less myopic eye, actual enlargement of the eye must play some role. Other features noted in grade I RLF were retinal pigmentation, vitreous membranes, and equatorial retinal folds. In grade II the most significant finding was dragging of the retina. It was noted that in all cases of dragging of the retina there were also peripheral retinal changes. Even more important, however, was the fact that peripheral retinal changes are often present when there are no changes in the posterior pole. Neovascularization, elevated retinal vessels, lattice degeneration, and retinal breaks were other features of grade II retinopathy. Significant was the fact that the incidence of lattice in patients with cicatricial RLF (15%) was more than twice that of the normal population. Grade III RLF was characterized by falciform retinal folds, and grade IV, by retinal detachment. Thirty-nine retinal detachments were rhegmatogenous and usually had temporal retinal breaks. Retinal detachments of a tractional exudative variety (14 eyes) tended to occur earlier in life than the rhegmatogenous variety. In infants, they were preceded by increased tortuosity of the vessels in the posterior pole and, sometimes, accumulation of exudation, both ominous prognostic signs.

Entities:  

Mesh:

Year:  1979        PMID: 95419     DOI: 10.1016/s0161-6420(79)35346-5

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  16 in total

1.  Vitreous Bands Identified by Handheld Spectral-Domain Optical Coherence Tomography Among Premature Infants.

Authors:  Emily M Zepeda; Ayesha Shariff; Thomas B Gillette; Laura Grant; Leona Ding; Kristina Tarczy-Hornoch; Michelle T Cabrera
Journal:  JAMA Ophthalmol       Date:  2018-07-01       Impact factor: 7.389

2.  Microcornea associated with retinopathy of prematurity.

Authors:  S P Kelly; A R Fielder
Journal:  Br J Ophthalmol       Date:  1987-03       Impact factor: 4.638

3.  Retinopathy of prematurity: late complications in the baby boomer generation (1946-1964).

Authors:  Bradley T Smith; William S Tasman
Journal:  Trans Am Ophthalmol Soc       Date:  2005

4.  Late traction detachment in retinopathy of prematurity or ROP-like cases.

Authors:  R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-07       Impact factor: 3.117

5.  Late visual field changes following cryotherapy for retinopathy of prematurity stage 3.

Authors:  I Kremer; I Nissenkorn; M Lusky; Y Yassur
Journal:  Br J Ophthalmol       Date:  1995-03       Impact factor: 4.638

6.  Dominant exudative vitreoretinopathy and other vascular developmental disorders of the peripheral retina.

Authors:  C E van Nouhuys
Journal:  Doc Ophthalmol       Date:  1982-09-23       Impact factor: 2.379

7.  Recurrent proliferations in macular pucker, diabetic retinopathy, and retrolental fibroplasialike disease after vitrectomy.

Authors:  E de Juan; H M Lambert; R Machemer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1985       Impact factor: 3.117

8.  Long term visual outcomes in laser treated threshold retinopathy of prematurity in Central Saudi Arabia.

Authors:  Abdullah G Al-Otaibi; Sultan S Aldrees; Ahmed A Mousa
Journal:  Saudi J Ophthalmol       Date:  2012-06-07

9.  Follow-up study on premature infants with and without retinopathy of prematurity.

Authors:  R Robinson; M O'Keefe
Journal:  Br J Ophthalmol       Date:  1993-02       Impact factor: 4.638

10.  Ocular findings in prematurely born children at 5 years of age.

Authors:  K Tuppurainen; E Herrgård; A Martikainen; M Mäntyjärvi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-05       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.